April 12th 2024
Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Immunotherapy Shakes Up Cervical Cancer Treatment Paradigm
February 17th 2022In an interview with Lt Col Yovanni Casablanca, MD, discussed the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.
Read More
Cemiplimab FDA Approval Application for Recurrent or Metastatic Cervical Cancer Withdrawn
January 28th 2022Ahead of its Prescription Drug User Fee Act target action date, the supplemental biologics license application for cemiplimab as treatment of metastatic cervical cancer has been withdrawn.
Read More
Immunotherapy Sparks Excitement for New Cervical Cancer Treatments
January 25th 2022Immunotherapy has especially demonstrated broad activity in cervical cancer, fueling development in this area and providing further signs of hope for new treatment options to come into the landscape with greater efficacy and manageable safety profiles.
Read More
Cervical Cancer Awareness Month: Trials Assess New Immunotherapies
January 19th 2022Margarett C. Ellison, MD, MHA, FACS, FACOG, gynecologic oncologist for Gynecologic Oncology of Tallahassee, a Division of Florida Cancer Specialists & Research Institute, reviews potential immunotherapy treatments for Cervical Cancer Awareness Month.
Read More
PR-Driven Approaches to Treating Granulosa Cell Tumors
October 16th 2021Even though most early stage adult patients with granulosa cell tumors experience an excellent outcome, up to 33% of patients will eventually develop a tumor relapse. Recurrence may be detected many years after the initial treatment, thus prolonged surveillance is necessary.
Read More
FDA Approves Pembrolizumab With Chemotherapy for PD-L1+ Recurrent or Metastatic Cervical Cancer
October 13th 2021Pembrolizumab is now FDA approved in combination with chemotherapy and with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1.
Read More
FDA Grants Priority Review to Cemiplimab for Recurrent/Metastatic Cervical Cancer
September 28th 2021The FDA has accepted and granted priority review to the supplemental biologics license application for the PD-1 inhibitor cemiplimab-wlc for the treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.
Read More